Portfolio
BioCurate’s portfolio of projects spans a number of therapeutic areas, from oncology to anti-infectives. These projects are currently receiving support from the BioCurate team and our network of local and global industry and sector partners.
Pio Therapeutics (Pio Tx) is a new company that will focus on expediting further development of its first-in-class agonist antibody, PIO-001. This is a selective agonistic anti-IL-21 monoclonal antibody that has been designed to amplify the bioactivity of endogenously produced IL-21, proportional to its localised expression. This approach will overcome clinical challenges associated with recombinant IL-21, take advantage of an antibody as a therapeutic modality, and allow combinatorial approaches with other therapeutics to be easily developed.
The research that led to the discovery and initial characterisation of PIO-001 was conducted at Monash University, in the laboratories of Professor Charles Mackay, Professor Di Yu, and Dr Remy Robert.
Click here for more information
Portfolio
BioCurate’s portfolio of projects spans a number of therapeutic areas, from oncology to anti-infectives. These projects are currently receiving support from the BioCurate team and our network of local and global industry and sector partners.
As an independent ‘venture catalyst’ and technology accelerator, BioCurate operates in the under-resourced, yet critical early phases of new drug development – a period often referred to as the ‘valley of death’ due to the high rate of project attrition.
Mr John Citizen
Executive Director, Biometrics Company
Portfolio
BioCurate’s portfolio of projects spans a number of therapeutic areas, from oncology to anti-infectives. These projects are currently receiving support from the BioCurate team and our network of local and global industry and sector partners.
As an independent ‘venture catalyst’ and technology accelerator, BioCurate operates in the under-resourced, yet critical early phases of new drug development – a period often referred to as the ‘valley of death’ due to the high rate of project attrition.